TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Patient Education on Kidney Recipients Knowledge, Coping and Quality of Life. A Randomized Controlled Trial.
Brief Summary: For patients with end-stage kidney disease, transplantation is the treatment of choice, offering improved quality of life by restored metabolism and freedom from dialysis. However, demands regarding the acquirement of knowledge in life post transplantation are high. In order to reduce rejection episodes, graft loss and the negative consequences of life-long immunosuppressive medication, it is essential for kidney recipients to possess knowledge about important aspects regarding immunosuppressive medication, graft surveillance and the benefit of specific lifestyle behavior. Consequently, patient education is required for this patient group. This randomized controlled trial is investigating the effect of a structured patient education program on kidney recipients' knowledge, coping and quality of life


Options:
A: Arm Label: Arm A-Tacrolimus then Envarsus; Type: EXPERIMENTAL; Interventions: Drug: Envarsus XR, Drug: Tacrolimus | Arm Label: Arm B-Envarsus then Tacrolimus; Type: EXPERIMENTAL; Interventions: Drug: Envarsus XR, Drug: Tacrolimus | Intervention Type: DRUG; Name: Envarsus XR; Assigned to Arm(s): Arm A-Tacrolimus then Envarsus, Arm B-Envarsus then Tacrolimus | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Arm A-Tacrolimus then Envarsus, Arm B-Envarsus then Tacrolimus
B: Arm Label: Patient education program; Type: EXPERIMENTAL; Interventions: Behavioral: Patient education program | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patient education program; Assigned to Arm(s): Patient education program
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: behavioral adaptation and symptom management | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: behavioral adaptation and symptom management; Assigned to Arm(s): 1
D: Arm Label: Conventional Patient education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient education | Arm Label: Patient education via Tablet computer; Type: EXPERIMENTAL; Interventions: Behavioral: Patient education | Intervention Type: BEHAVIORAL; Name: Patient education; Assigned to Arm(s): Conventional Patient education, Patient education via Tablet computer

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Myfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic Syndrome
Brief Summary: Study objective: To investigate the potential therapeutic efficacy of enteric-coated mycophenolate sodium combined with low-dose corticosteroid as first-line treatment for minimal change nephrotic syndrome (MCNS).


Options:
A: Arm Label: High dose prednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Arm Label: Alfacalcidol and low dose prednisolone; Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Drug: Alfacalcidol | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Alfacalcidol and low dose prednisolone, High dose prednisolone | Intervention Type: DRUG; Name: Alfacalcidol; Assigned to Arm(s): Alfacalcidol and low dose prednisolone
B: Intervention Type: DRUG; Name: long term tapering of prednisolone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: standard prednisolone treatment; Assigned to Arm(s): N/A
C: Arm Label: Myfortic plus low-dose steroid; Type: EXPERIMENTAL; Interventions: Drug: Myfortic plus low-dose steroid | Arm Label: Standard-dose steroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Intervention Type: DRUG; Name: Myfortic plus low-dose steroid; Assigned to Arm(s): Myfortic plus low-dose steroid | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Standard-dose steroid
D: Arm Label: prednisone 60 mg/meter square Body Surface Aera; Type: ACTIVE_COMPARATOR; Interventions: Drug: prednisone 60 mg/meter square Body Surface Area | Arm Label: prednisone 45 mg/meter square BSA; Type: ACTIVE_COMPARATOR; Interventions: Drug: prednisone 45 mg | Arm Label: prednisone 30 mg/meter squer BSA; Type: ACTIVE_COMPARATOR; Interventions: Drug: prednisone 30 mg | Intervention Type: DRUG; Name: prednisone 60 mg/meter square Body Surface Area; Assigned to Arm(s): prednisone 60 mg/meter square Body Surface Aera | Intervention Type: DRUG; Name: prednisone 45 mg; Assigned to Arm(s): prednisone 45 mg/meter square BSA | Intervention Type: DRUG; Name: prednisone 30 mg; Assigned to Arm(s): prednisone 30 mg/meter squer BSA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Center, Open Label, Randomized Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes
Brief Summary: A single center, open label, randomized, clinical trial comparing ApoB/ApoA ratio of Vytorin 10/20mg vs atorvastatin 20mg treatment.

DM2 patients will be screened for inclusion criteria. Patients (n=66 in each arm) will be randomized to either Ezetimibe/simvastatin 10/20mg or atorvastatin 20mg after 4 week washout or TLC period. Primary and secondary endpoints will be assessed at week 12.

Primary endpoint:

1) change of ApoB/ApoA ratio at week 12.

Secondary endpoint:

1. Change of lipid parameters (TC, LDL-C, HDL-C, TG, apoB 48) at week 12.
2. Change of HbA1C at week 12.
3. Change of HOMA index at week 12

   - HOMA =\[Fasting insulin (mIU/L) × Fasting glucose (mmol/L)\] / 22.5
4. Change of hsCRP at week 12
5. Safety assessment

Hypotheses:

* Three months treatment of Vytorin 10/20mg will be superior to atorvastatin 20mg in ApoB/ApoA ratio.
* In DM patients, Ezetimibe/Simvastatin Combination will be well-tolerated.


Options:
A: Arm Label: atorvastatin arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin | Arm Label: Lovaza arm; Type: EXPERIMENTAL; Interventions: Drug: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin | Intervention Type: DRUG; Name: Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin; Assigned to Arm(s): Lovaza arm | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): atorvastatin arm
B: Arm Label: simvastatin/ezetimibe (vytorin) group; Type: EXPERIMENTAL; Interventions: Drug: simvastatin/ezetimibe | Arm Label: atorvastatin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin 20mg | Intervention Type: DRUG; Name: simvastatin/ezetimibe; Assigned to Arm(s): simvastatin/ezetimibe (vytorin) group | Intervention Type: DRUG; Name: atorvastatin 20mg; Assigned to Arm(s): atorvastatin group
C: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
D: Arm Label: LCP-AtorFen; Type: EXPERIMENTAL; Interventions: Drug: LCP-AtorFen | Arm Label: atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin | Arm Label: fenofibrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: fenofibrate | Intervention Type: DRUG; Name: LCP-AtorFen; Assigned to Arm(s): LCP-AtorFen | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): atorvastatin | Intervention Type: DRUG; Name: fenofibrate; Assigned to Arm(s): fenofibrate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers. A Pragmatic Cluster Randomized Controlled Trial
Brief Summary: Earlier diagnoses and improved treatments have contributed to the growing cohort of cancer survivors. Nevertheless, these patients remain at risk for adverse long-term or late physical or psychosocial effects of cancer and its treatment. There is increasing recognition to improve information disclosure and cancer survivorship care. The American Institute of Medicine (IOM) and Health Council of the Netherlands both recommend that cancer survivors receive a summary of their course of treatment as a formal document, that also includes recommendations for subsequent cancer surveillance, management of late effects, and strategies for health promotion, the Survivorship Care Plan (SCP). However, no evidence exists concerning the positive and negative effects of the implementation of the SCP in daily clinical practice. The purpose of this study is to assess the impact of SCP care in routine clinical practice on cancer survivors' satisfaction with information disclosure and care, quality of life, illness perception, and health care use.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SCP care; Type: EXPERIMENTAL; Interventions: Other: SCP care | Intervention Type: OTHER; Name: SCP care; Assigned to Arm(s): SCP care
B: Arm Label: intervention group; Type: ACTIVE_COMPARATOR; Interventions: Device: distress thermometer | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: distress thermometer; Assigned to Arm(s): intervention group
C: Arm Label: minimal surveillance; Type: OTHER; Interventions: Other: surveillance program after completion of primary treatment | Arm Label: intensive surveillance; Type: OTHER; Interventions: Other: surveillance program after completion of primary treatment | Intervention Type: OTHER; Name: surveillance program after completion of primary treatment; Assigned to Arm(s): intensive surveillance, minimal surveillance
D: Arm Label: 1A; Type: N/A; Interventions: N/A | Arm Label: 1B; Type: N/A; Interventions: N/A | Arm Label: IIA; Type: N/A; Interventions: N/A | Arm Label: IIB; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers. A Pragmatic Cluster Randomized Controlled Trial
Brief Summary: Earlier diagnoses and improved treatments have contributed to the growing cohort of cancer survivors. Nevertheless, these patients remain at risk for adverse long-term or late physical or psychosocial effects of cancer and its treatment. There is increasing recognition to improve information disclosure and cancer survivorship care. The American Institute of Medicine (IOM) and Health Council of the Netherlands both recommend that cancer survivors receive a summary of their course of treatment as a formal document, that also includes recommendations for subsequent cancer surveillance, management of late effects, and strategies for health promotion, the Survivorship Care Plan (SCP). However, no evidence exists concerning the positive and negative effects of the implementation of the SCP in daily clinical practice. The purpose of this study is to assess the impact of SCP care in routine clinical practice on cancer survivors' satisfaction with information disclosure and care, quality of life, illness perception, and health care use.


Options:
A: Arm Label: Survivorship Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Survivorship Intervention | Arm Label: Facing Forward; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Facing Forward | Intervention Type: BEHAVIORAL; Name: Survivorship Intervention; Assigned to Arm(s): Survivorship Intervention | Intervention Type: BEHAVIORAL; Name: Facing Forward; Assigned to Arm(s): Facing Forward
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Stress Reduction | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Stress Reduction; Assigned to Arm(s): 1
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SCP care; Type: EXPERIMENTAL; Interventions: Other: SCP care | Intervention Type: OTHER; Name: SCP care; Assigned to Arm(s): SCP care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Yoga | Arm Label: 2; Type: OTHER; Interventions: Other: Delayed yoga classes | Intervention Type: BEHAVIORAL; Name: Yoga; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Delayed yoga classes; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Brief Summary: This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg for approximately a further 3 years. It will provide data on long term safety, tolerability and efficacy of siponimod in the RRMS patient population


Options:
A: Arm Label: BAF312 10 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 2 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 1.25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .5 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): BAF312 .25 mg/2 mg, BAF312 .5 mg/2 mg, BAF312 1.25 mg/2 mg, BAF312 10 mg/2 mg, BAF312 2 mg/2 mg
B: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Other: Placebo | Arm Label: Ocrelizumab 600 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ocrelizumab | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 600 mg, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Brief Summary: This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg for approximately a further 3 years. It will provide data on long term safety, tolerability and efficacy of siponimod in the RRMS patient population


Options:
A: Arm Label: Siponimod (BAF312); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): Siponimod (BAF312) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: BAF312 10mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 2 mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 0.5 mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 dose between 0.1 to 8 mg period 2; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 dose between 0.1 - 8 mg period 2; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo (period 1, 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): BAF312 0.5 mg (period 1), BAF312 10mg (period 1), BAF312 2 mg (period 1), BAF312 dose between 0.1 - 8 mg period 2, BAF312 dose between 0.1 to 8 mg period 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (period 1, 2)
C: Arm Label: BAF312 10 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 2 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 1.25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .5 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): BAF312 .25 mg/2 mg, BAF312 .5 mg/2 mg, BAF312 1.25 mg/2 mg, BAF312 10 mg/2 mg, BAF312 2 mg/2 mg
D: Arm Label: Subjects Assigned to BAF312; Type: N/A; Interventions: Procedure: Blood Draw, Procedure: CSF collection by lumbar puncture (Optional) | Arm Label: Subjects Assigned to Placebo (Controls); Type: N/A; Interventions: Procedure: Blood Draw, Procedure: CSF collection by lumbar puncture (Optional) | Intervention Type: PROCEDURE; Name: Blood Draw; Assigned to Arm(s): Subjects Assigned to BAF312, Subjects Assigned to Placebo (Controls) | Intervention Type: PROCEDURE; Name: CSF collection by lumbar puncture (Optional); Assigned to Arm(s): Subjects Assigned to BAF312, Subjects Assigned to Placebo (Controls)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention; PRATO-ACS Trial
Brief Summary: This open-label study, prospective, randomized trial evaluating the acute (in-hospital) pleiotropic and clinical effects of a hydrophilic statin (rosuvastatin) in patients with acute coronary syndrome


Options:
A: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment
B: Arm Label: Rosuvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rosuvastatin | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: rosuvastatin | Intervention Type: DRUG; Name: rosuvastatin; Assigned to Arm(s): 1, control
D: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dietary Maneuvers to Reduce Production of Colon-Derived Uremic Solutes
Brief Summary: This study will assess whether dietary fiber supplements can reduce the production of chemicals which are produced by colon bacteria and normally excreted from the body by the kidney, but build up in the body in patients on hemodialysis.


Options:
A: Arm Label: Probiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Probiotic | Arm Label: Prebiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Prebiotic | Arm Label: Symbiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Symbiotic | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotic; Assigned to Arm(s): Prebiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Symbiotic; Assigned to Arm(s): Symbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Corn Starch; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Corn starch | Arm Label: Fiber; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fiber | Intervention Type: DIETARY_SUPPLEMENT; Name: Fiber; Assigned to Arm(s): Fiber | Intervention Type: DIETARY_SUPPLEMENT; Name: Corn starch; Assigned to Arm(s): Corn Starch
C: Arm Label: HSCB, Brooklyn, NY; Type: N/A; Interventions: N/A | Arm Label: 2. Nephrology Associates,; Type: N/A; Interventions: N/A | Arm Label: 3.New York Harbor VA Medical Center; Type: N/A; Interventions: N/A | Arm Label: 4.Hospital Juarez De Mexico; Type: N/A; Interventions: N/A | Arm Label: 5. Hospital Italiano de Buenos Aires; Type: N/A; Interventions: N/A | Arm Label: 6. National Hospital; Type: N/A; Interventions: N/A
D: Arm Label: probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic; Assigned to Arm(s): probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Safety, Efficacy, and Feasibility of Medical Abortion Provided by Physicians and Non-physicians in Nepal: a Randomized Controlled, Equivalence Trial.
Brief Summary: The purpose of the study is to compare the safety, effectiveness, and acceptability of medical abortion provided by doctors and midlevel providers in a developing country where doctors are scarce, such as Nepal. This study is the first to evaluate the independent provision of medical abortion by trained nurses and auxiliary nurse midwives compared to doctors by assessing differences in safety, clinical outcomes, case management decision-making, and acceptability. This study provides scientifically valid data on the administration of medical abortion by midlevel providers working independently in a low-resource, developing country setting. The evidence generated by the study will assist policy makers in developing countries interested in expanding safe abortion services by eliminating the legal requirement limiting prescription of medical abortion to doctors where medical abortion is not restricted by law.


Options:
A: Arm Label: misoprostol by midwife; Type: OTHER; Interventions: Other: misoprostol by midwife | Arm Label: Misoprostol by physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: misoprostol by midwife; Assigned to Arm(s): misoprostol by midwife
B: Arm Label: midwife; Type: EXPERIMENTAL; Interventions: Other: Midwife | Arm Label: Physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Midwife; Assigned to Arm(s): midwife
C: Arm Label: Midlevel provider; Type: OTHER; Interventions: Other: Type of provider | Arm Label: Physician arm; Type: OTHER; Interventions: Other: Type of provider | Intervention Type: OTHER; Name: Type of provider; Assigned to Arm(s): Midlevel provider, Physician arm
D: Arm Label: Buccal; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol, Device: Semi-quantitative pregnancy test | Arm Label: Sublingual; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol, Device: Semi-quantitative pregnancy test | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Buccal, Sublingual | Intervention Type: DEVICE; Name: Semi-quantitative pregnancy test; Assigned to Arm(s): Buccal, Sublingual

Answer: C